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Geneticists are sometimes criticised for tending to ignore the environment. In experimental organisms, its effects can either be tightly controlled or assumed to be randomised across genotypes. Equally, epidemiologists may disregard genetic variation, again assuming it to be randomly distributed across exposed groups. In human genetics, it is now possible to stratify the population by genotype (Mendelian randomisation 2 ) and to examine the effects of environmental exposures largely free from the measurement biases that have dogged association studies in the past. This renewed focus on the environment is especially pertinent in genetically complex disorders where environment often plays the major role. The recent proposal to conduct a prospective cohort study of 500 000 individuals from throughout the UK (BioBank UK) is an attempt to integrate the genetic and environmental components of disease risk. 3 It is a population-based cohort and its prospective nature and large scale provide a future resource for understanding specific gene-environmental interactions in a wide range of conditions, from drug response to heart disease and cancer risk. The goal is not gene discovery but the identification of interactions between identified genes and environmental factors of public health significance. It will be costly, with a proposed £40 million to recruit and obtain baseline epidemiological information but, inevitably, a much larger sum will be required to carry out detailed investigations on cohort subsets. It is jointly funded by the UK Medical Research Council, the Wellcome Trust and the Department of Health and would recruit volunteers in the 45-69 year age group. It would be accessible to academic and industrial users, on a non-exclusive basis. The study raises interesting questions as to the specific or general utility of such a large resource.
A statistical definition of geneenvironment interaction would be a departure from expectation for the joint effect of genotype and environmental exposure. This implies a prior hypothesis, so that the presence or absence of interaction may depend on whether, for example, an additive or multiplicative model is used 4 ( Figure 1 ). A statistical definition may therefore lack a clear biological interpretation. A test for interaction is also contingent on the scale of measurement, although continuously varying scales and absolute rates (of disease or exposure) would seem to provide more biologically meaningful scales than relative rates. For example, the combined effect of the oral contraceptive pill in carriers of the factor V Leiden mutation (about 5% of the population) is to raise the incidence of venous thrombosis from 0.8 (per 10 000 person years) to 28.5, compared with 3.0 and 5.7 respectively for oral contraceptive and factor V Leiden mutation alone. 5 The joint effect is therefore greater than the sum of the individual risks and the greater absolute risk for one exposed genotype relative to another implies a synergistic and biologically relevant interaction. The commonly used relative risk for the interaction is however close to 1.0, implying no interaction on a multiplicative model. The likelihood of a real biological interaction is reinforced by evidence that both act within the clotting cascade and that there is a 100-fold increased incidence of thrombosis in homozygotes with the factor V Leiden mutation who take the contraceptive pill. 5 Lack of interaction is easier to define. Complex traits are by their nature strongly influenced by environment and it is commonplace for domesticated or laboratory animals with one genotype to show trait differences as the environment changes, but the rank order or proportional difference between genotypes does not change, so there is no interaction component (Figure 1b, c) . In plant and animal breeding, the definition of interaction is often confined to the specific situation where there is an opposite environmental effect in alternative genotypes, such that the rank order changes 6 ( Figure 1f ). This situation is uncommon in human genetics, but an interaction can be seen when exposure to different environments disproportionately alters the trait difference between genotypes, again with the implication of synergy or antagonism as opposed to independence (Figure 1d, e) . Risk may or may not be increased when a specific genotype or environment is present alone.
Some of the relatively small number of proposed gene-environment interactions relevant to human disease are shown in Table 1 . The interaction between smoking and ␣1-antitrypsin (PI) genotype is well established, in which the risk of chronic obstructive pulmonary disease increases exponen- tially with copy number of the PI*Z allele. 7 In this case, the rank order of genotypes is not altered, as is presumed to occur with carriers vs noncarriers of the sickle cell haemoglobin allele (HBB*S) in the presence or absence of malarial infection. The majority of known gene-environment interactions influencing human disease are of small effect. A variety of weak effects on cancer risk with relative risks of 1-2 have been reported for the GSTM1, NAT-2, CYP1A1 and CYP2D6 genes, some of which show detectable interactions with tobacco smoke or aromatic hydrocarbons. 8 In contrast, drug interactions are very well represented and the wide range of clinically important pharmacogenetic interactions 9, 10 suggests that the absence of past selection against such adverse effects leaves an Achilles heel in what is otherwise a robust and highly buffered system capable of metabolising a diverse set of natural compounds. It may be that many of the variants that are now the culprits in
The Pharmacogenomics Journal adverse drug responses were positively selected in the past, increasing their allele frequencies and contributing to the high rate of adverse responses when faced with new pharmaceutical challenges. This raises the wider issue of whether genetic variants influencing disease have also been under selection, raising the frequency of favoured alleles that are now deleterious in a changed environment. On these grounds, genes concerned with the metabolic effects of drought, starvation and immune response are among the best candidates for common gene-environment interactions (eg in salt-sensitive hypertension, type 2 diabetes mellitus and autoimmune disorders).
The 'environment' means the sum total of non-genetic influences from conception to death. It includes differences in sex, physical, psychological and cultural factors. Most such influences are simply not measurable so why is so much importance attached to the study of those few that can be measured? Environmental factors are thought to be primarily responsible for the large changes in disease incidence that have occurred within the last 50 years in type 2 diabetes mellitus, coronary artery disease, asthma, hypertension, various cancers, autoimmune and other diseases. 11 This implies that the relatively major lifestyle and dietary changes occurring within this period might be causally related. The possibility of environmental intervention raises the stakes but it is not clear that genetic variation in the population has any part at all in such temporal trends. In cardiovascular disease, indirect evidence suggests that established risk factors such as inappropriate diet, physical inactivity and tobacco explain 50-75% of the population incidence. 12 Identifying causal risk factors can be difficult, and most cases of cardiovascular disease arise in people who are not judged to be at high risk. 4, 12 Some common disorders are thought to be influenced by the intrauterine environment, such as varying exposure to steroid hormones and, in most disorders, the pathological changes commence decades before disease supervenes. The great majority of such influences are not easily measurable and even the more accessible influences, such as diet, show changing patterns across time, confusing causal associations. Environmental factors are also often highly correlated, so that those eating a high fat diet also have high meat and low fibre diets, making it difficult to know which is causal. The combined use of genetic and environmental data should help to reduce the influence of such confounding factors. An association between disease and a gene concerned with, for example, the metabolism of fatty acids or heterocyclic aromatic www.nature.com/tpj amines in meat, could help clarify which agents are causal. The goal of identifying gene-environment interactions is therefore necessarily limited, since only a small minority of environmental influences are measurable, but it is an issue of public health importance because of the possibility of practical intervention strategies. Specific goals of the study might include using genotypic data to:
(a) increase understanding of disease aetiology, which may lead to new preventive or therapeutic strategies. (b) definitively identify environmental hazards, such as dietary factors, that modify disease risk. It has not been possible to clearly identify causal exposures largely because of lack of measurement precision (eg recall bias in case-control studies), lack of power and inability to resolve confounding variables. (c) identify high risk groups for targeted prevention strategies. This goal has been questioned on the grounds that: (i) the increased risks are usually modest since most individuals with complex disease do not fall into identifiable high risk groups; and (ii) targeted individuals find behavioural change difficult. 13 (d) improve prognostic advice (eg risk for exposed vs non-exposed groups by genotype). (e) achieve health economic benefits (eg effective prevention within a genetic subgroup with a high population attributable risk). The problem is that genetically identified subgroups do not usually have large attributable risks since risks are generally small and the extent of exposure further limits subgroup size-hence the proposal to target whole populations for intervention strategies. 13 There is little doubt about the potential importance of the endeavour but how common are gene-environment interactions for disease, rather than for drug response, and will they be identifiable? The inherent difficulty of measuring interactions in human populations makes the first question hard to answer but what the BioBank UK study offers is the potential to carry out large-sample studies capable of detecting small effects (eg risk ratios of at least 2, even for the rarest disorders) relatively free from the bias of retrospective data collection. This may reduce the number of false-positive associations but how many interactions are likely to be identifiable? The short answer is probably many with small interaction effects and risk ratios of 1-2 but few of these will be biologically or clinically useful. Those with larger risk ratios will be fewer but potentially easier to identify, assuming the appropriate gene has been found by other means. The susceptibility genes that are currently being ident-ified in complex disease are those with effects on disease at the upper end of the phenotypic spectrum, almost all of which are large enough to be detectable by linkage and which show risk allele penetrances in the range 1-10%. 14 The numerous susceptibility loci with smaller effects will be more subject to environmental modification and interaction but the key point is that many will be too small to measure even in large studies. The majority of identified quantitative trait loci (QTL) individually explain less than 5% of the phenotypic variance and only a small proportion show 'major' QTL effects accounting for Ͼ10% of the variance. 15 By definition, single genes exerting large and uniform phenotypic effects are not usually subject to strong environmental modification and yet these are arguably the ones of most clinical and biological interest since, like mitotic checkpoint and mismatch repair genes in colorectal cancer, they are closest to the key, rate-limiting steps in the disease process. Those that are most subject to environmental modification are in general (but not always) numerous, of small effect and mostly acting at points that are far removed from the biologically interesting disease mechanisms. The most useful interactions are therefore those that lie between these two poles, genes with large-to-moderate effects that are also more likely to be detectable rather than submerged in a sea of genetic heterogeneity and small effects. 16 The situation with pharmacogenetic responses may be considerably more favourable, since the complexity of genetic effects influencing drug responses is likely to be less than with susceptibility to complex disorders such as coronary artery disease or hypertension. However, success may still require specific approaches such as identifying those towards the clinical extremes of responsiveness, where genetic effects are greater and the chance of detecting individual interactions is better in the presence of a clearly defined and measurable exposure such as a drug. The BioBank UK study also offers the possibility of links to prescribing information from primary care practitioners and hospi-
The Pharmacogenomics Journal tals so that, together with the clear definition and contrasting of exposures, the 500 000 cohort's greatest utility may lie in this context. A problem that remains is that while links to drug prescription data are good, information on drug response is more difficult to obtain. Linking to adverse drug events (the yellow card system) captures the more severe reactions and there are curated databases that link prescribing information to this and other information sources.
In contrast to drug responses, it has been difficult enough to identify genes conferring susceptibility to complex disease in any context, far less one that is contingent on a specific environmental exposure. This is partly because groups with clearly defined, measurable and contrasting exposures are hard to identify. A suitably contrasting exposure might be the lifestyle and dietary differences between Pima Indians living in Arizona and Mexico, which are associated with large differences in the prevalence of obesity and type 2 diabetes. 17 The context of the BioBank UK study is one in which 'gene discovery' has already been successful and common disease alleles are known. The current epidemic of type 2 diabetes in western societies is shown by a 50-60% increase in the past 10 years, 18 so that it is vital to exploit new strategies to find interventions that slow or arrest this and other worrying trends. Pharmacogenomics is at the forefront of the search for preventative and therapeutic agents while health providers and governments are in the business of promoting realistic lifestyle changes, but in either case, basic information relating genotype to environment is currently lacking. The public are weary of dietary recommendations that constantly change, so that geneticists and epidemiologists now have an opportunity to pool their resources and to provide hard evidence to justify such change. There are strategic questions however which need to be addressed.
The proposed study design is a 10-year plus longitudinal cohort study of normal individuals aged between 45 and 69 years, with the aim of carrying out genetic association studies with known genes. Incident cases with a variety of common disorders can therefore be prospectively identified and the large size of the study will provide sufficient power to detect risk ratios of 2 or more. The study is designed to identify at least 1000 incident cases of the commoner cancers and other diseases of public health importance during the initial 5 year follow-up. The availability of a dense set of single nucleotide polymorphism (SNP) markers is seen to provide some of the necessary tools for fine scale genetic dissection in which specific exposures or behaviour can be analysed in the context of genotypes. Study power is a function of validity and precision of measurement (hence the prospective design) but it is also a function of biology, and the first question is whether it is possible to identify sufficient numbers of uniformly exposed vs non-exposed groups in advance of gene discovery, since the study assumes that relevant genes will be discovered by other means in the course of the study. Science normally proceeds in a pragmatic, reductionist manner by addressing specifically targeted questions. In this case, specific hypotheses cannot be formulated or studies designed in advance of gene identification. Against this is set the provision of a large cohort with baseline ethnic, dietary, disease, family history, drug and other information on which to focus further studies. For example, once a new susceptibility gene is identified in which environmental interactions may be important, the initial step might be to use the large cohort to select a uniform study group that is unbiased with respect to trait or disease ascertainment and that minimises the influence of confounding influences such as ethnic, lifestyle, socioeconomic or other factors. Having selected a suitable study group, measured exposures could be analysed. Genotyping would follow either using the whole group or those at the extremes of exposure (eg highest 25% vs lowest 25%).
There is an inverse relationship between the scale of the study and the number of measures that can be made for a given cost. The BioBank UK study is large for one principal reason, which is to include enough incident cases (ie Ն1000 cases/5 year period) of less common but clinically important disorders to detect small risk ratios. A substantially smaller cohort would be required if more intensive phenotypic analysis could be carried out. Unfortunately, it is currently impossible to increase power by studying endophenotypes or intermediate disease endpoints in several clinically important disorders, including cancer. Endophenotypes are subclinical quantitative traits, such as lipid profiles or measures of glucose intolerance, that provide more specific disease-related phenotypes than disease, often because they are more directly related to gene action than categorical traits. 19 Common diseases result from many independent, correlated or interacting risk factors operating over a lifetime. Ideally, a limited set of endophenotypes that are under independent genetic control, might account for a significant proportion of the genetic component of risk. They provide a natural scale for measuring geneenvironment interactions, in contrast to binary traits (affected or unaffected), in which the choice of scale, and hence definition of interaction, may be arbitrary. 4 The importance of using endophenotypes to minimise disease complexity is seldom questioned and would be particularly appropriate for cancer, where different sets of genes are known to be involved at each stage of progression towards and beyond the neoplastic state. 20 At the present time, relevant endophenotypes are also not readily measurable in most psychiatric and neurological disorders, whereas they have been widely and successfully used to study a range of other conditions including cardiovascular, respiratory and metabolic disorders. The measurement of quantitative endophenotypes results in a substantially higher proportion of the cohort being informative for genetic analysis so that a smaller cohort would provide equivalent or greater power than the large cohort.
Clayton and McKeigue 4 argue that justification for the greater cost of a www.nature.com/tpj prospective cohort study is less than clear cut since it is possible to ascertain subjects by phenotype and then to use genotype to effectively randomise all other variables. Case-control studies using such Mendelian randomisation can therefore reduce costs and eliminate much of the measurement bias that has made it so difficult to measure small gene-environment interactions in the past. They also point up the difficulty of distinguishing departures from the multiplicative model, especially where there may be measurement errors or where the interaction model is not specified correctly. However, even with genotypic randomisation, retrospective measurement bias still introduces noise into the system and reduces power. The inherent costliness of the BioBank UK study also has to be weighed against the advantage of a large, currently available cohort on whom extensive health information is available, which can provide a platform from which to launch a variety of add-on studies, not least because many of the relevant variables will not have been measured in advance.
Genotyping studies carried out in a large disease cohort is an inefficient means of detecting interactions. The most powerful tool in the genetic armoury is, and always has been, the ascertainment of individuals at increased genetic risk compared with the average, by using information such as familial correlations, disease onset or severity ( Table 1 ). The same argument can be applied to the study of gene-environment interactions, which also tend to be correlated within families compared with random, unrelated individuals. If there is no familial correlation for a trait, it is less likely to be significantly influenced by genetic, common environmental or interaction effects. The high background of non-genetic phenotypes or cases is minimised in this way. Failure to provide a mechanism for this will result in loss of power due to the low signal-to-noise. Selection of individuals based solely on an extreme trait value is not enough to minimise non-genetic influences when environment is the predominant causal influence, as shown by heritabilities that are rarely above 50% and which frequently decline with age-of-onset [21] [22] [23] [24] as somatic aging and stochastic factors take their toll.
In genetically complex disease a family history is often not present, because the genetic influence is rapidly dispersed within a family (eg because it is oligogenic or polygenic). Other family members may however be at increased genetic risk due to an abnormal endophenotype. The presence of disease is contingent on the cumulative effect of several risk factors, so that disease risk declines exponentially with relationship to an affected member. Alternatively, there may be no family history simply because the genetic risks are small. Failure to provide a means of distinguishing these alternatives seriously limits the value of the BioBank UK study. The ability to measure familial correlations is a powerful means of separating genetic from random effects, principally by enriching for those at increased or decreased risk relative to the population average. This is the subgroup who will be most informative from a genetic, environmental or interaction standpoint. Those with average disease risk or trait values simply reduce the signal-to-noise. The majority of individuals with a disease are at average risk 13 and are the ones most likely to show weak and multigenic effects, which will be influenced by environment, but are of a magnitude that makes them either undetectable or uninteresting. The availability of a smaller, intensively phenotyped cohort, with sib pairs or nuclear families to examine familial correlations between the trait and genotype or exposure, will help maximise the enrichment for those showing moderate-to-large interaction effects over those that represent stochastic variability, weak genetic influences and contributing most to an inherently noisy system.
The 500 000 cohort could provide a platform from which to recruit a subcohort of around 20 000 sib pairs and parents, so as to include a familial component to the study. This would provide sufficient power to detect small relative risks in the more common disorders, while still providing Ͼ1000 incident cases (per 5 year follow-up) within the smaller cohort. 25 In the case of quantitative endophenotypes, even greater power is available to detect allele frequency differences at the extremes. Intensive phenotyping would only need to be carried out on the sibs rather than on parents. In order to minimise ascertainment bias due to death of one or both parents, recruitment would have to be restricted to a younger age group, such as the 45-50 year age range. This would be an advantage for many disorders, such as coronary artery disease, since: (i) disease-related endophenotypes may be abnormal for years or even decades before disease supervenes; (ii) those showing abnormal endophenotypes at an earlier age provide enrichment for a more extreme genetic subgroup, who are more likely to show individually detectable interactions; (iii) the high background of disease or abnormal traits due to non-genetic factors will be minimised in the younger age group but maximised in the oldest age group (as heritability declines). Same-sex sib pairs would be the most useful group but mixed sib pairs provide additional information on environmental interactions. A parent-sib pair sub-cohort would provide considerable added value:
¼ the ability to make use of familial correlations to increase power using strategies such as the EDAC ('extreme discordant and concordant') design. 26 This design selects for sib pairs that are either concordant for extreme values (high or low) or, less commonly, extremely discordant for the trait or endophenotype. Selection of sibships on the basis of one extreme proband is also a powerful strategy which reduces cost. 27 ¼ the ability to use linkage-based strategies or combined linkage and association for gene discovery extends the general utility of the study. Linkage, unlike association analysis, is robust in the presence of multiple susceptibility alleles, so that a parent sib-pair sub-cohort
The Pharmacogenomics Journal could provide an enormously useful resource for gene discovery as well as for interaction studies. Given the scale of investment and restricted range of possible environmental measures, a national resource is more readily justified if it has broad utility. The success or failure of the study is currently predicated on the discovery of new susceptibility genes, which is rate limiting. Inclusion of a familial component allows the resource to be used to significantly advance that process and would seem to be an outstanding scientific opportunity. ¼ the ability to obtain information on genetic haplotypes-combinations of variants at neighbouring loci on a single chromosomal background. These provide essential information for genotypic and risk assessment. Alleles influencing complex traits are commonly determined by combinations of variants within and outside of coding regions, 28 so that haplotypes rather than single variants tend to influence risk. Haplotype information is most readily determined with the help of family information, despite recent improvements in prediction. 29 It can be argued that the distribution of haplotypes is more efficiently predicted in populations than in individuals, which will serve the purpose for case-control comparisons. However such predictions are most reliable over short compared with extended genetic distances, which is an important limitation especially if the resource is extended to gene discovery. The only absolute method of haplotype determination is to segregate chromosomal pairs in somatic cell hybrids 30 which could only be realistically carried out in a cohort subset. ¼ The ability to carry out transmission-disequilibrium tests (TDT) and to use 'pseudocontrol' data by the comparison of transmitted with non-transmitted parental alleles. 31 The high frequency of apparent false-positive results in human genetic association studies 32 suggests that it is as important for geneticists to use non-transmitted allele controls as it is for epidemiologists to avoid retrospective data collection wherever possible. The UK is one of the most genetically diverse and stratified populations in Europe, so that opportunities for false-positive associations abound. The frequencies of common susceptibility alleles (q Ͼ 0.10) may show small differences between most founder populations but the differences are much greater for alleles that appear likely to influence disease susceptibility, with frequencies in the range 0.001-0.10.
14,33
The alternative method for avoiding such false-positives is to use 'genomic control', which corrects for stratification by measuring the extent of association between unlinked markers. 34 This approach is very useful but, at the present time, the use of parentally non-transmitted alleles represents the gold standard for association studies. If the UK is to assemble one of the largest and most expensive population cohorts ever, it surely requires the most robust method available for the provision of control data. ¼ the ability to provide parent-of-origin information, which may be vital for analysing the effects of parental influences on adult disease. 35 There is increasing evidence for a relationship between early life events and a variety of adult diseases, some of which may involve maternally or paternally imprinted loci, such as IGF2 and its receptor. 36 Maternalfoetal interactions may influence adult diseases ranging from coronary artery disease to stroke, hypertension and type 2 diabetes. 37 The primary goals of a large geneenvironment cohort study are not to understand disease in 'typical' affected individuals, which the biological complexity tells us is hopelessly unrealistic, but to identify biological mechanisms or pathways which lead to novel preventive measures or drug targets. The priority is therefore to identify large-to-moderate rather than average genetic interaction effects using the most powerful ascertainment strategies available. It is ironic that the identification of Ͼ1000 disease genes in the course of the Human Genome Mapping Project was built on the platform of recruiting families showing extreme phenotypes and yet it is increasingly being abandoned in favour of population-based studies with the extension to less penetrant genetic effects and more common disorders, where the need for enrichment strategies should be even greater. In Mendelian disorders, families are essential to enrich for the presence of rare disease alleles, but if individual susceptibility alleles are common, population samples (cases/controls) can be contrasted and increased power is available to detect small effects. This falls down when allelic heterogeneity is common, when susceptibility alleles are at low or intermediate frequencies (eg q = 0.001-0.1) and when non-genetic factors are the major contributors to phenotypic diversity (even extreme diversity) in the population.
14 Enrichment strategies are again required, based not on family history of disease but on familial correlations for high or low endophenotype values, disease onset, severity and other factors ( Table 2 ). The 500 000 cohort therefore has limited value unless intensively phenotyped subgroups and familial components are included. As always, the devil lies in the detail, much of which remains to be finalised.
The following major conclusions can be drawn:
¼ A prospective cohort study, which identifies at least 1000 incident cases even of relatively uncommon diseases, provides the best platform for generating unbiased data on environmental risk factors. The addition of genotypic data provides a potentially powerful means of disentangling correlated and confounding exposures. However, the availability of genetic randomisation to reduce bias in case-control studies makes the substantially higher cost of the large cohort (n = 500 000) less clear-cut. ¼ most environmental variables relevant to common diseases are either not measurable or not reliably measurable, even with the best www.nature.com/tpj Table 2 Ascertainment strategies for increasing the heritability or reducing heterogeneity of a complex trait ¼ Familial correlation (eg family history of disease or, for complex traits, sib pairs who are correlated for risk factors such as elevated cholesterol or blood pressure). ¼ Early age-of-onset, relative to the population norm (eg in breast or colorectal cancer and heart disease, age-of-onset may be a more sensitive indicator of a significant genetic component than family history. A familial correlation in age-of-onset is especially useful when the recurrence risks for disease are low). ¼ Severe disease (eg bipolar depression, schizoaffective disorder). ¼ Endophenotypes (measures can be chosen that minimise the effect of environmental variation, eg cholesterol ratios (total/HDL, LDL/HDL) are valid risk factors in populations with widely differing mean cholesterol levels 51 ). ¼ Genetic subgroup (eg colorectal cancer subjects without mismatch repair defects or HLAmatched type 1 diabetics). ¼ Low environmental risk (eg non-smokers with chronic obstructive pulmonary disease or bronchial cancer). ¼ High environmental risk (eg smokers who develop lung cancer. This assumes that environmental exposure plus a high risk genotype results in interaction and increased susceptibility. As argued in the text, the signal:noise ratio here is very low so that it is generally more efficient to identify susceptibility factors in low exposure groups and then test for interactions). ¼ High prevalence group (eg type 2 diabetes mellitus in Micronesions or Mexican Americans (rural vs urban), hypertension in black Africans, primary open-angle glaucoma in blacks and Caribbeans). ¼ Less affected sex (eg in systemic lupus erythematosus there is a 9:1 female:male sex difference in prevalence, and increased recurrence risks in relatives of male compared with female subjects, implying stronger genetic effects). ¼ Population isolate (eg north American religious sects, isolated populations with 'small founder pools', or young populations in which genetic associations are substantially stronger (larger regions of linkage disequilibrium) than in large urban populations 16 ).
study designs. The focus of a geneenvironment interaction study is therefore on a highly restricted subset of exposures that are both reliably measured and potentially modifiable and hence of public health significance. The recent changes in prevalence of many common diseases suggests that such modifiable influences (eg diet, lifestyle) may be major contributors. ¼ a major issue is whether recent changes in disease prevalence are influenced by gene-environment interactions rather than being independent of genetic variation. Assuming such interactions are present, it is also unclear whether they will be individually detectable, rather than being mediated by very many genes of small effect (polygenes), which are those that are generally most subject to environmental modification. ¼ a sub-cohort of sib pairs and parents (eg 20 000 sib pairs), on whom intensive phenotype analysis has been carried out, would provide a valuable means of increasing the genetic signal-to-noise. Other ways of achieving this are summarized in Table 2 . This would facilitate the identification of gene-environment interactions that are of clinical or public health significance. ¼ the inclusion of a familial component (eg parent-sib pairs) as well as an intensively phenotyped subcohort would provide considerable added value by providing: (i) enrichment for genetic effects (using familial correlations); (ii) a robust source of control data for association studies (TDT test); (iii) improved haplotype prediction; (iv) parent-of-origin information; (v) the ability to extend the general utility of the resource by allowing gene discovery using combined linkage and association analysis. ¼ the relative ease of measuring adverse drug reactions in the cohort and access to information on drug prescription should facilitate the study of pharmacogenetic interactions. Measuring drug responses in population samples is more difficult but access to curated databases will be helpful.
